Clearmind Medicine News

Clearmind Medicine Advances MEAI-Based Alcohol Substitute Beverage Program

The global market of no- and low-alcohol beverages estimated at over $13 billion in 2023

BenzingaMay 10 20:26

Why Beyond Shares Are Trading Lower By Over 20%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Shares of Beyond, Inc. (NYSE:BYON) fell sharply during Tuesday's session following weaker-than-expected quarterly results.Beyond posted adjusted loss of $1.22 per share, versus estimates for a loss of

BenzingaMay 8 02:35

Why Clearmind Medicine Stock Is Moving Higher

Clearmind Medicine Inc. (NASDAQ:CMND) shares are up Tuesday after the company announced it signed an exclusive patent licensing agreement with Yissum Research Development.What Happened: The agreement

BenzingaMay 7 23:03

NanoViricides, TC BioPharm, Holdco Nuvo Among Healthcare Movers

Seeking AlphaMay 7 22:01

Market-Moving News for May 7th

CMND: 60% | Clearmind Medicine shares are trading higher after the company signed an exclusive patent licensing agreement with Yissum Research Development Company.HIMS: 18% | Hims & Hers Health share

BenzingaMay 7 20:36

Clearmind Medicine Shares Are Trading Higher After the Company Signed an Exclusive Patent Licensing Agreement With Yissum Research Development Company.

Clearmind Medicine Shares Are Trading Higher After the Company Signed an Exclusive Patent Licensing Agreement With Yissum Research Development Company.

BenzingaMay 7 19:49

UPDATE: Agreement Provides Clearmind With Exclusive Global Rights To Further Develop, Manufacture, And Commercialize Innovative Compounds Invented By Professors Rami Yaka, Ahmed Masaewa And Avi Priel From The Hebrew University

UPDATE: Agreement Provides Clearmind With Exclusive Global Rights To Further Develop, Manufacture, And Commercialize Innovative Compounds Invented By Professors Rami Yaka, Ahmed Masaewa And Avi Priel

BenzingaMay 7 19:48

Clearmind Medicine Signs Exclusive Patent Licensing Agreement With Yissum Research Development Company; Under Agreement, Clearmind Receives Exclusive Rights To Develop, Manufacture, And Commercialize Novel Compounds For Treating PTSD And Other Mental...

Clearmind Medicine Signs Exclusive Patent Licensing Agreement With Yissum Research Development Company; Under Agreement, Clearmind Receives Exclusive Rights To Develop, Manufacture, And Commercialize

BenzingaMay 7 19:47

Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment

Vancouver, Canada, May 07, 2024 -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development of novel

Clearmind MedicineMay 7 12:00

Clearmind Medicine Streamlines Reporting Obligations

TipRanksMay 1 21:19

Clearmind Applies to Cease Being a Reporting Issuer in Canada

Vancouver, Canada, April 30, 2024 -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical- stage biotech company focused on discovery and development of

Clearmind MedicineApr 30 12:00

Psychedelics Headlines: Dementia Prevention, Psychological Flexibility, Ancient Romans' Trips And More

Welcome to Benzinga's psychedelic headlines roundup. This is our pick of must-read news items from the first two weeks of April 2024.See previous edition Psychedelics Headlines: A Form Of Life, Treati

BenzingaApr 17 21:13

Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders

Tel Aviv, Israel / Vancouver, Canada, April 17, 2024 -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) ("Clearmind" or the "company"), a biotech company focused on discovery and development of no

Clearmind MedicineApr 17 12:00

Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders

Vancouver, Canada, April 10, 2024 -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) ("Clearmind" or the "company"), a clinical- stage biotech company focused on discovery and development of novel

Clearmind MedicineApr 10 12:00

Clearmind Medicine CEO Issues Letter to Shareholders

Vancouver, Canada, April 09, 2024 -- Clearmind Medicine Inc. (Nasdaq:CMND), (FSE:CWY0) ("Clearmind" or the "company"), a clinical-stage biotech company focused on discovery and development of novel ps

Clearmind MedicineApr 9 12:00

Psychedelics Headlines: A Form Of Life, Treating Chronic Pain, Microdosing And More

Welcome to Benzinga's psychedelic headlines roundup. This is our pick of must-read news items from the last two weeks of March 2024.See previous edition Psychedelics Headlines: Substitution Survey, Fr

BenzingaMar 30 20:57

Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence

Intranasal 5-MeO-DMT Clinical Trial Offers Hope For Treatment-Resistant DepressionPartners Beckley Psytech and atai Life Sciences (NASDAQ:ATAI) have jointly announced positive initial results from a P

BenzingaMar 30 00:43

SciSparc- Clearmind Collaboration Evolves With New International Patent Application for Preventing and Treating Depression

TEL AVIV, Israel, March 27, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to

GlobeNewswireMar 27 20:55

Clearmind Medicine Announces International Patent Application for Preventing and Treating Depression

Vancouver, Canada, March 27, 2024 -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY) ("Clearmind" or the "company"), a biotech company focused on discovery and development of novel psychedelic-deri

Clearmind MedicineMar 27 12:00

Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More

FDA Grants Cybin Breakthrough Therapy Status For Major Depression Psilocybin Therapy, Company Announces Positive Clinical Data & Canadian $150M Private PlacementClinical-stage psychedelics biopharma c

BenzingaMar 21 02:49